Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Novel Agents, Combos Transforming Treatment in MCL and CLL

October 14th 2019

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.

Long-Term Data Highlight Poor Prognosis With TP53-Mutant MCL

October 11th 2019

Ezzat Elhassadi, MD, discusses the results from a 10-year institutional analysis and how the presence of a TP53 mutation can correlate with survival outcomes in patients with mantle cell lymphoma.

Dr. Wang on Toxicity Profiles of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

October 9th 2019

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

BTK Combos Potentially Poised to Be New Standard MCL Treatment

October 9th 2019

Simon Rule, MD, discusses the standard of care for MCL treatment and future regimens that could transform clinical practice.

Dr. Gerson on the Watch-and-Wait Approach in MCL

October 7th 2019

James N. Gerson, MD, discusses the watch-and-wait approach for patients with mantle cell lymphoma.

Dr. Rule on the Future Therapeutic Landscape of MCL

October 4th 2019

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the future therapeutic landscape of mantle cell lymphoma.

Dr. Wang on Triplet Vorinostat Regimen in Newly Diagnosed MCL

September 25th 2019

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Dr. Zelenetz on Current Treatment Options for MCL

September 25th 2019

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

Targeted Agents Continue to Advance in MCL, With CAR T on the Horizon

September 24th 2019

Andrew D. Zelenetz, MD, PhD, discusses the use of emerging targeted therapies in mantle cell lymphoma.

Andre Goy: Giving Patients Strength to Fight

September 20th 2019

Andre Goy, MD, MS, discusses cutting-edge CAR T-cell therapy and other groundbreaking investigations, as well as his thoughts on general developments in oncology and hematology.

Dr. Wang on CAR T-Cell Therapy Resistance in MCL

September 20th 2019

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Intriguing Strategies Taking Shape in Mantle Cell Lymphoma

September 18th 2019

Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.

Dr. Zelenetz on Anticipated Research in MCL

September 18th 2019

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

Dr. Rule on Searching for a Biomarker Indicating Indolent MCL

September 17th 2019

Simon Rule, MD, discusses a study comparing patients with newly diagnosed mantle cell lymphoma who receive immediate systemic treatment immediately versus patients who are closely monitored instead.

Dr. Martin Discusses the Heterogeneity of MCL

September 11th 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses the heterogeneity of mantle cell lymphoma (MCL).

Dr. Wang on Combatting CAR T-Cell Therapy Resistance in MCL

September 6th 2019

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCL

September 4th 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

Vorinostat Triplet Elicits High Responses in Newly Diagnosed MCL

August 30th 2019

The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate of 97% and a complete response rate of 80% in newly diagnosed patients with mantle cell lymphoma.

FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma

August 22nd 2019

The FDA has granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with mantle cell lymphoma who have received ≥1 prior therapy.

Dr. Martin on Ibrutinib/Palbociclib Combo in Ibrutinib-Resistant MCL

August 16th 2019

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.